ClinicalTrials.gg
CompletedNCT04138056Updated Aug 21, 2024Results posted

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

A Phase 2 interventional study of RSVPreF3 formulation 3 and RSVPreF3 formulation 2 in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
509
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
23rd of 40
509 · median 642
Started
2019
with 5 others
Phase 2
9 of 40
none open now
Registered
14th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 23rd largest by enrollment, is one of 6 that started in 2019, is one of 9 in phase 2, and was the 14th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, ability of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree to which the vaccine can cause side effects, when administered alone and in combination with Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine] formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in an extension of the study to assess the durability of the immune response after the first dose vaccination, and to assess the safety and immunogenicity following a second dose vaccination of the RSVPreF3 maternal vaccine.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primary study

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the subject prior to performance of any study specific procedure.
  • Healthy female subjects; as established by medical history and clinical examination, aged 18 to 45 years at the time of the 1st vaccination;
  • Female subjects of may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to primary vaccination, and
    • has a negative pregnancy test on the day of primary vaccination, and
    • has agreed to continue adequate contraception for 90 days after completion of the vaccination.
  • No local condition precluding injection in both left and right deltoid muscles.

Extension study

  • Completed primary study and received 1st dose of a study vaccine.
  • Written or witnessed/thumb printed informed consent obtained from the subject prior to performance of any study specific procedure to the study extension.

All subjects must satisfy ALL the following criteria:

  • Subjects who can and will comply with the requirements of the protocol.
  • Female subjects remain healthy; as established by medical history and clinical examination, aged 18 to 45 years at the time of the 1st vaccination;
  • Female subjects of childbearing potential are eligible for the extension, if the subject:

    • has practiced adequate contraception for 30 days prior to 2nd vaccination
    • has a negative pregnancy test with results available on the day of 2nd vaccination
    • has agreed to continue adequate contraception for 90 days after completion of the 2nd vaccination.

Exclusion criteria

Exclusion Criteria:

Primary study

Medical conditions

  • History of any reaction/ likely to be exacerbated by any vaccines' component;
  • Any confirmed/suspected /immunodeficient condition, based on medical history and physical examination;
  • Hypersensitivity to latex;
  • Major congenital defects;
  • Acute/chronic pulmonary, cardiovascular, hepatic/renal functional abnormality;
  • Significant/uncontrolled psychiatric illness;
  • Recurrent history/uncontrolled neurological disorders/seizures;
  • Documented -positive subject;
  • History of/current disease;
  • (BMI)>40 kg/m\^2;
  • Any clinically significant hematological parameter and/or biochemical laboratory abnormality.
  • Any other clinical condition that might pose additional risk to the subject due to participation in the study.

Prior/Concomitant therapy

  • Use of any /non-registered product other than the study vaccines during the period starting 30 days before 1st vaccination, or planned use during the study;
  • Administration of long-acting immune-modifying drugs at any time during the study;
  • Administration of immunoglobulins and/or any blood products/plasma derivatives during the period starting 3 months before the 1st vaccination or planned administration during the study;
  • Chronic administration of immunosuppressants/other immune-modifying drugs during the period starting 3 months prior to 1st vaccine dose(s). For , this will mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study 1st vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before/after study vaccination;
  • Administration of a vaccine containing diphtheria, tetanus/pertussis antigens/diphtheria and tetanus toxoids within the previous 5 years;
  • Previous experimental vaccination against RSV;

Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study, in which the subject has been/will be exposed to an investigational/a non-investigational vaccine/product;

Other exclusions

  • Pregnant/lactating female;
  • Female planning to become pregnant/planning to discontinue precautions;
  • History of alcoholism, drug abuse and/or use disorder within the past 2 years;
  • Any study personnel/their immediate dependents, family/household members.

Extension study

Medical conditions

  • History of any reaction/hypersensitivity likely to be exacerbated by any component of the vaccines;
  • Any confirmed/suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination;
  • Hypersensitivity to latex;
  • Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality;
  • Significant/uncontrolled psychiatric illness;
  • Recurrent history/uncontrolled neurological disorders/seizures;
  • Documented HIV-positive subject;
  • History of/current autoimmune disease;
  • BMI>40 kg/m\^2;
  • Participants who experienced any SAE judged to be possibly or probably related to 1st dose of RSVPreF3, including hypersensitivity reactions.
  • Any other clinical condition that might pose additional risk to the subject due to participation in the study.

Prior/Concomitant therapy

  • Use of any investigational/non-registered product other than the study vaccines during the period starting 30 days before the 2nd vaccination, or planned use during the 6-month study extension;
  • Administration of long-acting immune-modifying drugs at any time during the study;
  • Administration of immunoglobulins and/or any blood products/plasma derivatives during the period starting 3 months before the 1st dose of study vaccines/planned administration during the study;
  • Chronic administration of immunosuppressants or other immune-modifying drugs during the starting 3 months prior to the 1st vaccine dose(s). For corticosteroids, this will mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study 2nd vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before/after study vaccination.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study, in which the subject has been/will be exposed to an investigational/a non-investigational vaccine/product;

Other exclusions

  • Pregnant/lactating female at the time of Visit 4;
  • Female planning to become pregnant/planning to discontinue contraceptive precautions;
  • History of alcoholism, drug abuse and/or use disorder within the past 2 years;
  • Any study personnel/their immediate dependents, family/household members.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
509 participants (actual)

Study arms

  • Experimental
    RSV120_dTpa_RSV120(Pooled)

    Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

    Biological: RSVPreF3 formulation 3 · Biological: Boostrix-ex-US · Biological: Boostrix-US

  • Placebo comparator
    RSV120_Placebo_RSV120(Pooled)

    Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

    Biological: RSVPreF3 formulation 3 · Drug: Placebo

  • Experimental
    RSV60_dTpa_RSV120(Pooled)

    Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

    Biological: RSVPreF3 formulation 3 · Biological: RSVPreF3 formulation 2 · Biological: Boostrix-ex-US · Biological: Boostrix-US

  • Placebo comparator
    RSV60_Placebo_RSV120(Pooled)

    Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

    Biological: RSVPreF3 formulation 3 · Biological: RSVPreF3 formulation 2 · Drug: Placebo

  • Placebo comparator
    dTpa_Placebo_RSV120(Pooled)

    Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

    Biological: RSVPreF3 formulation 3 · Biological: Boostrix-ex-US · Biological: Boostrix-US · Drug: Placebo

Interventions

  • BiologicalRSVPreF3 formulation 3

    One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.

  • BiologicalRSVPreF3 formulation 2

    One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.

  • BiologicalBoostrix-ex-US

    One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.

  • BiologicalBoostrix-US

    One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.

  • DrugPlacebo

    One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study]

    Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 8

  2. Percentage of Subjects With Any Solicited General AEs [Primary Study]

    Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever (body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 8

  3. Percentage of Subjects With Any Unsolicited AEs [Primary Study]

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 31

  4. Number of Subjects With Any SAEs [Primary Study]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 31

  5. Percentage of Subjects With Any Solicited Local AEs [Extension Study]

    Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From the Day of 2nd vaccination to Day 8 post 2nd vaccination

  6. Percentage of Subjects Any Solicited General AEs [Extension Period]

    Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From the Day of 2nd vaccination to Day 8 post 2nd vaccination

  7. Percentage of Subjects With Any Unsolicited AEs [Extension Period]

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From the Day of 2nd vaccination to Day 31 post 2nd vaccination

  8. Number of Subjects With Any SAEs [Extension Period]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From the Day of 2nd vaccination to Day 31 post 2nd vaccination

  9. RSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60 (Estimated Dilution 60). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Screening (Day -7 to Day 1)

  10. RSV A Neutralizing Antibody GMTs at Day 8 [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 8

  11. RSV A Neutralizing Antibody GMTs at Day 31 [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31

  12. RSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA ). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Screening (Day -7 to Day 1)

  13. RSV PreF3 IgG GMCs at Day 8 [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 8

  14. RSV PreF3 IgG GMCs at Day 31 [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31

Secondary outcomes

  1. Percentage of Subjects With Any Solicited Local Adverse Event (AEs) by Each Boostrix Formulation [Primary Study]

    Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 8

  2. Percentage of Subjects With Any Solicited General AEs by Each Boostrix Formulation [Primary Study]

    Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 8

  3. Percentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study]

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 31

  4. Number of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 31

  5. Number of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 181

  6. Number of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

    Time frame: From Day 1 to Day 181

  7. Number of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period]

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

    Time frame: From the Day of 2nd vaccination to Day 181 post 2nd vaccination

  8. RSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Screening (Day -7 to Day 1)

  9. RSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Day 8

  10. RSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31

  11. RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At a single timepoint between 12 to 18 months post 1st vaccination

  12. RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At a single timepoint between 12 to 18 months post 1st vaccination

  13. RSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study]

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31 post 2nd vaccination

  14. RSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Screening (Day -7 to Day 1)

  15. RSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Day 8

  16. RSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31

  17. RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.

    Time frame: At a single timepoint between 12 to 18 months post 1st vaccination

  18. RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At a single timepoint between 12 to 18 months post 1st vaccination

  19. RSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study]

    Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

    Time frame: At Day 31 post 2nd vaccination

  20. Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Screening (Day -7 to Day 1)

  21. Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Day 31

  22. Diphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Screening (Day -7 to Day 1)

  23. Diphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Day 31

  24. Tetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Screening (Day -7 to Day 1)

  25. Tetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

    Time frame: At Day 31

  26. Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening [Primary Study]

    Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Screening (Day -7 to Day 1)

  27. Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 [Primary Study]

    Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Day 31

  28. Diphtheria (Anti-D) GMCs at Screening [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Screening (Day -7 to Day 1)

  29. Diphtheria (Anti-D) GMCs at Day 31 [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Day 31

  30. Tetanus (Anti-T) GMCs at Screening [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Screening (Day -7 to Day 1)

  31. Tetanus (Anti-T) GMCs at Day 31 [Primary Study]

    Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

    Time frame: At Day 31

07

Results

Posted Dec 19, 2022

Participant flow

Primary Study
Participant flow — Primary Study
MilestoneRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Started101101103102102
Completed959310010098
Not completed68324
Withdrew: Lost to follow-up34114
Withdrew: Eligibility criteria not fulfilled (inclusion and exclusion criteria)34210
Extension Study
Participant flow — Extension Study
MilestoneRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Started3941464146
Completed3839454145
Not completed12101
Withdrew: Lost to follow-up12101

Outcome measures

PrimaryPercentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study]

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 8
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSVPreF3 (Left Arm), Erythema5.9 (2.2 to 12.5)5 (1.6 to 11.3)5.8 (2.2 to 12.2)5.9 (2.2 to 12.4)0 (0 to 3.7)
RSVPreF3 (Left Arm), Pain51.5 (41.3 to 61.6)54 (43.7 to 64)52.4 (42.4 to 62.4)58.8 (48.6 to 68.5)19.2 (12 to 28.3)
RSVPreF3 (Left Arm), Swelling2 (0.2 to 7)7 (2.9 to 13.9)2.9 (0.6 to 8.3)4.9 (1.6 to 11.1)0 (0 to 3.7)
dTpa (Right Arm), Erythema4 (1.1 to 9.8)1 (0 to 5.4)4.9 (1.6 to 11)1 (0 to 5.3)6.1 (2.3 to 12.7)
dTpa (Right Arm), Pain81.2 (72.2 to 88.3)25 (16.9 to 34.7)76.7 (67.3 to 84.5)18.6 (11.6 to 27.6)78.8 (69.4 to 86.4)
dTpa (Right Arm), Swelling5 (1.6 to 11.2)0 (0 to 3.6)1.9 (0.2 to 6.8)1 (0 to 5.3)4 (1.1 to 10)
PrimaryPercentage of Subjects With Any Solicited General AEs [Primary Study]

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever (body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 8
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Solicited General AEs [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Fatigue40.6 (30.9 to 50.8)39.6 (30 to 49.8)37.9 (28.5 to 48)32.4 (23.4 to 42.3)38.4 (28.8 to 48.7)
Gastrointestinal symptoms23.8 (15.9 to 33.3)28.7 (20.1 to 38.6)27.2 (18.9 to 36.8)28.4 (19.9 to 38.2)28.3 (19.7 to 38.2)
Headache44.6 (34.7 to 54.8)45.5 (35.6 to 55.8)35 (25.8 to 45)39.2 (29.7 to 49.4)37.4 (27.9 to 47.7)
Temperature2 (0.2 to 7)4 (1.1 to 9.8)2.9 (0.6 to 8.3)3.9 (1.1 to 9.7)7.1 (2.9 to 14)
PrimaryPercentage of Subjects With Any Unsolicited AEs [Primary Study]

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 31
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Unsolicited AEs [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Percentage of Subjects With Any Unsolicited AEs [Primary Study]38.6 (29.1 to 48.8)34.7 (25.5 to 44.8)33 (24.1 to 43)37.3 (27.9 to 47.4)32.4 (23.4 to 42.3)
PrimaryNumber of Subjects With Any SAEs [Primary Study]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs [Primary Study]
ParticipantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Number of Subjects With Any SAEs [Primary Study]00000
PrimaryPercentage of Subjects With Any Solicited Local AEs [Extension Study]

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From the Day of 2nd vaccination to Day 8 post 2nd vaccination
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Solicited Local AEs [Extension Study]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Erythema17.9 (7.5 to 33.5)10.3 (2.9 to 24.2)8.7 (2.4 to 20.8)14.6 (5.6 to 29.2)2.3 (0.1 to 12)
Pain87.2 (72.6 to 95.7)87.2 (72.6 to 95.7)80.4 (66.1 to 90.6)85.4 (70.8 to 94.4)38.6 (24.4 to 54.5)
Swelling12.8 (4.3 to 27.4)7.7 (1.6 to 20.9)8.7 (2.4 to 20.8)4.9 (0.6 to 16.5)2.3 (0.1 to 12)
PrimaryPercentage of Subjects Any Solicited General AEs [Extension Period]

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From the Day of 2nd vaccination to Day 8 post 2nd vaccination
Reported as:
Number · Percentage of participants
Percentage of Subjects Any Solicited General AEs [Extension Period]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Fatigue25.6 (13 to 42.1)33.3 (19.1 to 50.2)37 (23.2 to 52.5)46.3 (30.7 to 62.6)34.1 (20.5 to 49.9)
Gastrointestinal symptoms10.3 (2.9 to 24.2)20.5 (9.3 to 36.5)15.2 (6.3 to 28.9)24.4 (12.4 to 40.3)13.6 (5.2 to 27.4)
Headache28.2 (15 to 44.9)33.3 (19.1 to 50.2)32.6 (19.5 to 48)56.1 (39.7 to 71.5)31.8 (18.6 to 47.6)
Temperature0 (0 to 9)0 (0 to 9)2.2 (0.1 to 11.5)9.8 (2.7 to 23.1)2.3 (0.1 to 12)
PrimaryPercentage of Subjects With Any Unsolicited AEs [Extension Period]

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From the Day of 2nd vaccination to Day 31 post 2nd vaccination
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Unsolicited AEs [Extension Period]
Percentage of participantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Percentage of Subjects With Any Unsolicited AEs [Extension Period]18 (8 to 34)20 (9 to 35)20 (9 to 34)29 (16 to 46)20 (9 to 34)
PrimaryNumber of Subjects With Any SAEs [Extension Period]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From the Day of 2nd vaccination to Day 31 post 2nd vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs [Extension Period]
ParticipantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Number of Subjects With Any SAEs [Extension Period]00010
PrimaryRSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60 (Estimated Dilution 60). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV A Neutralizing Antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]875 (745 to 1027)1022 (856 to 1222)1135 (959 to 1342)771 (673 to 883)1050 (896 to 1231)
PrimaryRSV A Neutralizing Antibody GMTs at Day 8 [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 8
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing Antibody GMTs at Day 8 [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV A Neutralizing Antibody GMTs at Day 8 [Primary Study]14166 (12213 to 16431)14285 (11999 to 17008)10185 (8514 to 12183)10590 (8994 to 12469)783 (661 to 929)
PrimaryRSV A Neutralizing Antibody GMTs at Day 31 [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing Antibody GMTs at Day 31 [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV A Neutralizing Antibody GMTs at Day 31 [Primary Study]9836 (8252 to 11725)11038 (9160 to 13301)9214 (7806 to 10876)8739 (7561 to 10101)845 (705 to 1013)
PrimaryRSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA ). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · ELISA Units per milliliter (EU/mL)
RSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]
ELISA Units per milliliter (EU/mL)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV PreF3 IgG Antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]6611 (5857 to 7461)6751 (5982 to 7620)7449 (6534 to 8492)6172 (5570 to 6840)6454 (5771 to 7217)
PrimaryRSV PreF3 IgG GMCs at Day 8 [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 8
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Day 8 [Primary Study]
EU/mLRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV PreF3 IgG GMCs at Day 8 [Primary Study]156568 (137244 to 178613)146708 (128639 to 167315)101662 (89783 to 115113)118670 (106004 to 132850)5780 (5145 to 6494)
PrimaryRSV PreF3 IgG GMCs at Day 31 [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Day 31 [Primary Study]
EU/mLRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV PreF3 IgG GMCs at Day 31 [Primary Study]101813 (89290 to 116092)106082 (93597 to 120231)86273 (77415 to 96145)88938 (79738 to 99200)6149 (5474 to 6908)
SecondaryPercentage of Subjects With Any Solicited Local Adverse Event (AEs) by Each Boostrix Formulation [Primary Study]

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 8
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Solicited Local Adverse Event (AEs) by Each Boostrix Formulation [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
Left Arm, Erythema6 (1.3 to 16.5)4.1 (0.5 to 14)5.9 (1.2 to 16.2)2 (0 to 10.4)0 (0 to 7.3)5.9 (1.2 to 16.2)5.9 (1.2 to 16.2)5.8 (1.2 to 15.9)9.8 (3.3 to 21.4)0 (0 to 7.1)
Left Arm, Pain46 (31.8 to 60.7)53.1 (38.3 to 67.5)52.9 (38.5 to 67.1)60.8 (46.1 to 74.2)16.3 (7.3 to 29.7)56.9 (42.2 to 70.7)54.9 (40.3 to 68.9)51.9 (37.6 to 66)56.9 (42.2 to 70.7)22 (11.5 to 36)
Left Arm, Swelling2 (0.1 to 10.6)6.1 (1.3 to 16.9)3.9 (0.5 to 13.5)2 (0 to 10.4)0 (0 to 7.3)2 (0 to 10.4)7.8 (2.2 to 18.9)1.9 (0 to 10.3)7.8 (2.2 to 18.9)0 (0 to 7.1)
Right Arm, Erythema4 (0.5 to 13.7)2 (0.1 to 10.9)2 (0 to 10.4)2 (0 to 10.4)6.1 (1.3 to 16.9)3.9 (0.5 to 13.5)0 (0 to 7)7.7 (2.1 to 18.5)0 (0 to 7)6 (1.3 to 16.5)
Right Arm, Pain86 (73.3 to 94.2)18.4 (8.8 to 32)88.2 (76.1 to 95.6)23.5 (12.8 to 37.5)79.6 (65.7 to 89.8)76.5 (62.5 to 87.2)31.4 (19.1 to 45.9)65.4 (50.9 to 78)13.7 (5.7 to 26.3)78 (64 to 88.5)
Right Arm, Swelling6 (1.3 to 16.5)0 (0 to 7.3)3.9 (0.5 to 13.5)2 (0 to 10.4)6.1 (1.3 to 16.9)3.9 (0.5 to 13.5)0 (0 to 7)0 (0 to 6.8)0 (0 to 7)2 (0.1 to 10.6)
SecondaryPercentage of Subjects With Any Solicited General AEs by Each Boostrix Formulation [Primary Study]

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree celcius/100.4 degree Farenhit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 8
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Solicited General AEs by Each Boostrix Formulation [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
Fatigue36 (22.9 to 50.8)36.7 (23.4 to 51.7)39.2 (25.8 to 53.9)29.4 (17.5 to 43.8)34.7 (21.7 to 49.6)45.1 (31.1 to 59.7)42.3 (28.7 to 56.8)36.5 (23.6 to 51)35.3 (22.4 to 49.9)42 (28.2 to 56.8)
Gastrointestinal symptoms22 (11.5 to 36)28.6 (16.6 to 43.3)23.5 (12.8 to 37.5)29.4 (17.5 to 43.8)30.6 (18.3 to 45.4)25.5 (14.3 to 39.6)28.8 (17.1 to 43.1)30.8 (18.7 to 45.1)27.5 (15.9 to 41.7)26 (14.6 to 40.3)
Headache46 (31.8 to 60.7)38.8 (25.2 to 53.8)31.4 (19.1 to 45.9)45.1 (31.1 to 59.7)40.8 (27 to 55.8)43.1 (29.3 to 57.8)51.9 (37.6 to 66)38.5 (25.3 to 53)33.3 (20.8 to 47.9)34 (21.2 to 48.8)
Temperature4 (0.5 to 13.7)6.1 (1.3 to 16.9)3.9 (0.5 to 13.5)5.9 (1.2 to 16.2)12.2 (4.6 to 24.8)0 (0 to 7)1.9 (0 to 10.3)1.9 (0 to 10.3)2 (0 to 10.4)2 (0.1 to 10.6)
SecondaryPercentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study]

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 31
Reported as:
Number · Percentage of participants
Percentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study]
Percentage of participantsRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
Percentage of Subjects With Any Unsolicited AEs by Each Boostrix Formulation [Primary Study]38 (24.7 to 52.8)36.7 (23.4 to 51.7)39.2 (25.8 to 53.9)43.1 (29.3 to 57.8)33.3 (20.8 to 47.9)39.2 (25.8 to 53.9)32.7 (20.3 to 47.1)26.9 (15.6 to 41)31.4 (19.1 to 45.9)31.4 (19.1 to 45.9)
SecondaryNumber of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study]
ParticipantsRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
Number of Subjects With Any SAEs by Each Boostrix Formulation [Primary Study]0000000000
SecondaryNumber of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 181
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study]
ParticipantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 [Primary Study]10000
SecondaryNumber of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3.

Time frame:
From Day 1 to Day 181
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study]
ParticipantsRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
Number of Subjects With Any SAEs From 1st Vaccination to Day 181 by Each Boostrix Formulation [Primary Study]1000000000
SecondaryNumber of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period]

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3.

Time frame:
From the Day of 2nd vaccination to Day 181 post 2nd vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period]
ParticipantsRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Number of Subjects With Any SAEs From 2nd Vaccination to Day 181 Post 2nd Vaccination [Extension Period]00010
SecondaryRSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV A Neutralizing GMTs at Screening by Each Boostrix Formulation [Primary Study]777 (625 to 966)1009 (798 to 1277)989 (749 to 1307)777 (631 to 956)956 (740 to 1236)981 (773 to 1245)1035 (786 to 1362)1298 (1070 to 1574)765 (638 to 917)1154 (952 to 1399)
SecondaryRSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Day 8
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV A Neutralizing GMTs at Day 8 by Each Boostrix Formulation [Primary Study]14523 (11831 to 17827)15458 (12424 to 19231)10677 (8146 to 13993)11128 (8885 to 13939)698 (530 to 918)13818 (11070 to 17248)13264 (10075 to 17462)9715 (7612 to 12400)10077 (7897 to 12858)884 (722 to 1082)
SecondaryRSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV A Neutralizing GMTs at Day 31 by Each Boostrix Formulation [Primary Study]9838 (7987 to 12118)10800 (8675 to 13446)8754 (6821 to 11236)8141 (6545 to 10125)767 (575 to 1023)9834 (7354 to 13152)11276 (8283 to 15351)9698 (7735 to 12159)9395 (7726 to 11425)930 (740 to 1168)
SecondaryRSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At a single timepoint between 12 to 18 months post 1st vaccination
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]2034 (1458 to 2836)2869 (1998 to 4119)3086 (2143 to 4445)2200 (1522 to 3180)675 (495 to 920)2014 (1190 to 3411)2960 (1190 to 7362)2474 (1741 to 3517)2569 (1586 to 4160)969 (602 to 1560)
SecondaryRSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At a single timepoint between 12 to 18 months post 1st vaccination
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]
Titers (ED60)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV A Neutralizing GMTs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]2027 (1546 to 2656)2889 (2086 to 4001)2885 (2204 to 3778)2302 (1730 to 3064)759 (588 to 980)
SecondaryRSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study]

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31 post 2nd vaccination
Reported as:
Geometric mean · Titers (ED60)
RSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study]
Titers (ED60)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV A Neutralizing GMTs at Day 31 Post 2nd Vaccination [Extension Study]3892 (3016 to 5022)5071 (3848 to 6683)4779 (3747 to 6094)4920 (3886 to 6231)8200 (6380 to 10539)
SecondaryRSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study]
EU/mLRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV PreF3 IgG GMCs at Screening by Each Boostrix Formulation [Primary Study]6240 (5159 to 7548)6524 (5597 to 7604)7237 (5905 to 8869)6106 (5275 to 7067)5907 (5077 to 6873)6987 (5975 to 8170)6978 (5764 to 8447)7662 (6447 to 9107)6240 (5375 to 7245)7051 (5973 to 8324)
SecondaryRSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Day 8
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study]
EU/mLRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV PreF3 IgG GMCs at Day 8 by Each Boostrix Formulation [Primary Study]155721 (133435 to 181728)143104 (126138 to 162352)100064 (84699 to 118216)123475 (107405 to 141950)5523 (4700 to 6490)157403 (126554 to 195772)150184 (119250 to 189142)103286 (85400 to 124919)114053 (95089 to 136799)6061 (5097 to 7207)
SecondaryRSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
EU/mLRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV PreF3 IgG GMCs at Day 31 by Each Boostrix Formulation [Primary Study]94254 (80742 to 110026)95113 (83282 to 108624)84509 (72281 to 98805)81915 (70291 to 95460)5600 (4777 to 6565)109978 (88643 to 136446)118052 (95525 to 145892)88075 (75406 to 102872)96727 (82608 to 113258)6739 (5678 to 7999)
SecondaryRSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3.

Time frame:
At a single timepoint between 12 to 18 months post 1st vaccination
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]
EU/mLRSV120_dTpa_RSV120(EX-US)RSV120_Placebo_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)RSV60_Placebo_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV120_Placebo_RSV120(US)RSV60_dTpa_RSV120(US)RSV60_Placebo_RSV120(US)dTpa_Placebo_RSV120(US)
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination by Each Boostrix Formulation [Primary Study]18832 (15141 to 23423)20894 (16466 to 26512)23189 (18629 to 28864)20720 (16689 to 25726)5014 (3932 to 6392)18127 (10969 to 29958)19641 (9143 to 42195)22905 (17801 to 29471)22233 (15931 to 31029)6811 (5005 to 9269)
SecondaryRSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At a single timepoint between 12 to 18 months post 1st vaccination
Reported as:
Geometric mean · EU/mL
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]
EU/mLRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV PreF3 IgG GMCs at Single Time Point Between 12 to 18 Months Post 1st Vaccination [Primary Study]18570 (14961 to 23049)20605 (16333 to 25995)23102 (19586 to 27249)21152 (17777 to 25168)5540 (4581 to 6700)
SecondaryRSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study]

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled), RSV120_Placebo_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3.

Time frame:
At Day 31 post 2nd vaccination
Reported as:
Geometric mean · (IU/mL)
RSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study]
(IU/mL)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
RSV PreF3 IgG GMCs at Day 31 Post 2nd Vaccination [Extension Study]41399 (34806 to 49241)42943 (37226 to 49537)43977 (38784 to 49865)45680 (38574 to 54094)86934 (75442 to 100177)
SecondaryPertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · International Units Per mL (IU/mL)
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening by Each Boostrix Formulation [Primary Study]
International Units Per mL (IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
anti-PT7.39 (5.11 to 10.68)7.64 (5.47 to 10.66)6.65 (4.66 to 9.47)7.55 (5.34 to 10.66)5.66 (4.06 to 7.88)7.17 (4.94 to 10.41)
anti-FHA32.8 (23 to 46.7)34.5 (24.3 to 49.1)29.3 (22 to 38.9)31 (22.7 to 42.4)29.6 (22.5 to 38.9)28 (21 to 37.4)
anti-PRN43.2 (27.9 to 66.7)39 (25.3 to 60.1)28.1 (18.2 to 43.4)42.1 (27.6 to 64.2)40.1 (26.9 to 60)28.7 (17.9 to 46.1)
SecondaryPertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Day 31
Reported as:
Geometric mean · (IU/mL)
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
(IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
anti-PT57.36 (41.82 to 78.69)54.95 (44.78 to 67.44)79.16 (62.67 to 99.98)43.76 (34.1 to 56.17)36.98 (28.25 to 48.42)44.99 (34.81 to 58.15)
anti-FHA237.1 (194.1 to 289.5)210.6 (168.5 to 263.1)303.6 (241.6 to 381.5)186.5 (149.8 to 232.3)176.7 (139.3 to 224.1)232.9 (182.2 to 297.8)
anti-PRN309.5 (226.7 to 422.6)214.7 (166.8 to 276.4)395.1 (290.3 to 537.6)217.7 (153.7 to 308.3)228.1 (161.9 to 321.5)331.4 (238.4 to 460.5)
SecondaryDiphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · (IU/mL)
Diphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study]
(IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
Diphtheria (Anti-D) GMC at Screening by Each Boostrix Formulation [Primary Study]0.26 (0.18 to 0.39)0.27 (0.17 to 0.42)0.23 (0.16 to 0.32)0.46 (0.33 to 0.64)0.55 (0.42 to 0.73)0.58 (0.43 to 0.78)
SecondaryDiphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Day 31
Reported as:
Geometric mean · (IU/mL)
Diphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
(IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
Diphtheria (Anti-D) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]1.3 (0.97 to 1.73)1.18 (0.85 to 1.63)1.76 (1.25 to 2.48)2.11 (1.61 to 2.76)2.2 (1.72 to 2.81)3.29 (2.62 to 4.14)
SecondaryTetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · (IU/mL)
Tetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study]
(IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
Tetanus (Anti-T) GMCs at Screening by Each Boostrix Formulation [Primary Study]1.14 (0.87 to 1.5)1.1 (0.78 to 1.54)0.88 (0.64 to 1.22)1.35 (1.01 to 1.81)1.56 (1.27 to 1.92)1.68 (1.29 to 2.19)
SecondaryTetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum).

Time frame:
At Day 31
Reported as:
Geometric mean · (IU/mL)
Tetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]
(IU/mL)RSV120_dTpa_RSV120(EX-US)RSV60_dTpa_RSV120(EX-US)dTpa_Placebo_RSV120(EX-US)RSV120_dTpa_RSV120(US)RSV60_dTpa_RSV120(US)dTpa_Placebo_RSV120(US)
Tetanus (Anti-T) GMCs at Day 31 by Each Boostrix Formulation [Primary Study]5.57 (4.64 to 6.7)5.3 (4.52 to 6.21)6.74 (5.79 to 7.84)6.09 (4.98 to 7.45)6.27 (5.29 to 7.44)8.32 (6.88 to 10.05)
SecondaryPertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening [Primary Study]

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · IU/mL
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Screening [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Anti-PT7.47 (5.83 to 9.57)6.56 (5.20 to 8.28)6.90 (5.36 to 8.89)
Anti-FHA31.9 (25.3 to 40.2)31.9 (25.6 to 39.8)28.6 (23.5 to 34.9)
Anti-PRN42.6 (31.6 to 57.4)39.6 (29.6 to 52.9)28.4 (20.7 to 38.9)
SecondaryPertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 [Primary Study]

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Day 31
Reported as:
Geometric mean · IU/mL
Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) GMCs at Day 31 [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Anti-PT50.10 (41.04 to 61.17)45.08 (38.00 to 53.48)59.51 (49.71 to 71.23)
Anti-FHA210.3 (181.4 to 243.8)192.9 (164.2 to 226.6)265.6 (224.7 to 313.8)
Anti-PRN259.6 (205.8 to 327.4)221.3 (179.5 to 272.9)361.1 (289.1 to 451.1)
SecondaryDiphtheria (Anti-D) GMCs at Screening [Primary Study]

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · IU/mL
Diphtheria (Anti-D) GMCs at Screening [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Diphtheria (Anti-D) GMCs at Screening [Primary Study]0.35 (0.27 to 0.45)0.39 (0.30 to 0.51)0.36 (0.28 to 0.47)
SecondaryDiphtheria (Anti-D) GMCs at Day 31 [Primary Study]

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Day 31
Reported as:
Geometric mean · IU/mL
Diphtheria (Anti-D) GMCs at Day 31 [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Diphtheria (Anti-D) GMCs at Day 31 [Primary Study]1.65 (1.35 to 2.01)1.59 (1.29 to 1.97)2.42 (1.96 to 2.99)
SecondaryTetanus (Anti-T) GMCs at Screening [Primary Study]

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Screening (Day -7 to Day 1)
Reported as:
Geometric mean · IU/mL
Tetanus (Anti-T) GMCs at Screening [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Tetanus (Anti-T) GMCs at Screening [Primary Study]1.24 (1.02 to 1.51)1.31 (1.08 to 1.60)1.22 (0.98 to 1.51)
SecondaryTetanus (Anti-T) GMCs at Day 31 [Primary Study]

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups \[RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)\] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Time frame:
At Day 31
Reported as:
Geometric mean · IU/mL
Tetanus (Anti-T) GMCs at Day 31 [Primary Study]
IU/mLRSV120_dTpa_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Tetanus (Anti-T) GMCs at Day 31 [Primary Study]5.83 (5.10 to 6.66)5.76 (5.13 to 6.47)7.49 (6.64 to 8.46)

Adverse events

Collected over Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after any vaccination. Serious adverse events were collected from Day 1 (Primary Study) to the Study End (Day 181 after the second RSVPreF3 vaccination, Extension Study).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV120_dTpa_RSV120(Pooled)0/101 (0%)1/101 (1%)92/101 (91.1%)
RSV120_Placebo_RSV120(Pooled)0/101 (0%)0/101 (0%)90/101 (89.1%)
RSV60_dTpa_RSV120(Pooled)0/103 (0%)0/103 (0%)91/103 (88.3%)
RSV60_Placebo_RSV120(Pooled)0/102 (0%)1/102 (1%)82/102 (80.4%)
dTpa_Placebo_RSV120(Pooled)0/102 (0%)0/102 (0%)89/102 (87.3%)
Most frequent serious events
Most frequent serious events
EventRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Radius fractureInjury, poisoning and procedural complications1/1010/1010/1030/1020/102
Ulna fractureInjury, poisoning and procedural complications1/1010/1010/1030/1020/102
Wrist fractureInjury, poisoning and procedural complications1/1010/1010/1030/1020/102
PyelonephritisInfections and infestations0/1010/1010/1031/1020/102
Most frequent other events
Showing 10 of 140
Most frequent other events
EventRSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)
Injection site pain - Extension StudyGeneral disorders34/3936/4137/4635/4118/46
Injection site pain - Primary StudyGeneral disorders86/10162/10184/10360/10281/102
Headache - Extension StudyNervous system disorders11/3915/4115/4623/4116/46
Headache - Primary StudyNervous system disorders47/10147/10138/10342/10237/102
Fatigue - Extension StudyGeneral disorders10/3915/4117/4619/4116/46
Fatigue - Primary StudyGeneral disorders42/10140/10139/10334/10238/102
Gastrointestinal disorder - Primary StudyGastrointestinal disorders24/10129/10128/10329/10228/102
Gastrointestinal disorder - Extension StudyGastrointestinal disorders4/3910/417/4610/417/46
Injection site erythema - Extension StudyGeneral disorders7/394/414/466/411/46
Injection site swelling - Extension StudyGeneral disorders5/393/414/462/411/46

Baseline characteristics

Age, Customized
Age, Customized(Years)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
Mean31.4 ± 7.631.0 ± 8.030.8 ± 8.430.5 ± 8.330.4 ± 7.930.8 ± 8.0
Age, Customized
Age, Customized(Years)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
Mean32.1 ± 7.931.7 ± 8.430.4 ± 8.630.3 ± 8.432.6 ± 8.231.4 ± 8.3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
Female101101103102102509
Male000000
Sex/Gender, Customized
Sex/Gender, Customized(Participants)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
Female3941464146213
Male000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
AMERICAN INDIAN OR ALASKA NATIVE301105
ASIAN1324414
BLACK OR AFRICAN AMERICAN4683425
OTHER Not specified2222311
WHITE9190909291454
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV120_dTpa_RSV120(Pooled)RSV120_Placebo_RSV120(Pooled)RSV60_dTpa_RSV120(Pooled)RSV60_Placebo_RSV120(Pooled)dTpa_Placebo_RSV120(Pooled)Total
AMERICAN INDIAN OR ALASKA NATIVE100001
ASIAN101204
BLACK OR AFRICAN AMERICAN001012
OTHER Not specified102014
WHITE3641423944202
08

Study locations

8 sites
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Seattle, Washington 98105, United States
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    London, Ontario N5W 6A2, Canada
09

References and documents

Publications

  • Hermida N, Ferguson M, Leroux-Roels I, Pagnussat S, Yaplee D, Hua N, van den Steen P, Anspach B, Dieussaert I, Kim JH. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study. J Infect Dis. 2024 Aug 16;230(2):e353-e362. doi: 10.1093/infdis/jiad560. PubMed 38133639 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Feb 2020, 3 months.

Results were first posted in Dec 2022, 2 years 9 months after primary completion. A results delay was requested in Jan 2021.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 3 months is below that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2019
First posted
Oct 24, 2019
StartActual
Nov 5, 2019
Primary completionActual
Feb 25, 2020
CompletionActual
Nov 22, 2021
Results delay requested
Jan 28, 2021
Results first posted
Dec 19, 2022
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04138056
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Nov 5, 2019
Primary completion
Feb 25, 2020
Completion
Nov 22, 2021
Results posted
Dec 19, 2022
Last update
Aug 21, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion